TradingView
AlenCiken
2018年7月13日晚上9點17分

CLBS granted regenerative medicine advanced therapy by FDA 看多

NASDAQ:CLBS240

描述

⋅
Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

caladrius.com/press-release/caladrius-receives-fda-regenerative-medicine-advanced-therapy-designation-for-cd34-cell-therapy-for-treating-refractory-angina/
Trend AnalysisChart PatternsTechnical Indicators
更多